NCT06854159
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06854159
Title Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Joseph Tuscano
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.